Drug intelligence / Profile preview

esaconazole

Development stage: Preclinical
Modality: Small Molecules

Overview

Esaconazole is an azole antifungal drug mentioned as an intervention in a clinical trial for Acute Myeloid Leukemia patients. While it is classified as an azole antifungal, detailed information regarding its specific mechanism of action, primary indication, or developer is not readily available in public sources. The Chinese name '艾莎康唑' (Aishakangzuo), which might be confused with esaconazole, actually refers to Isavuconazole, a different azole antifungal. 'Esaconazole sulfate' has been identified as a pharmaceutical intermediate.

Targets

CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on esaconazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on esaconazole.

Explore the full profile